UnknownPhase 2

Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.

Italy160 participantsStarted 2020-10-15

Plain-language summary

Anti-CD20 monoclonal antibodies are emerging as the steroid-sparing therapy of choice for nephrotic syndrome.This Randomized Clinical Trial seeks to evaluate whether Rituximab biosimilar maintains drug-free disease remission in patients with steroid-dependent nephrotic syndrome for 12-24 months and verify its superiority vs. mycophenolate mofetil (1,200 mg/m2 orally in 2 daily doses). The investigators will compare the risk of relapse to test this hypothesis (primary outcome). Secondary objectives will include assessing short- and long-term side-effects and developing specific biomarkers of sensitivity to therapy. Patients will be recruited, treated and followed at IRCCS G Gaslini and IRCCS Bambino Gesù where laboratory studies will be performed at in-site facilities.

Who can participate

Age range3 Years – 24 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age between 3 and 24 years * Prednison dependent steroid syndrome 0.3-1mg/Kg/day and receive prednisone for at least six months before enrolment. Steroid dependence is defined by two consecutive relapse during corticosteroid therapy or within 14 days of ceasing therapy. * Ability to provide consent and assent: parents'/guardian's written informed consent, and child's assent given before any study-related procedure not part of the subject's normal medical care, with the understanding that consent may be withdrawn by the subject any time without prejudice to his or her future medical care. Exclusion Criteria: * Positivity to autoimmunity tests (ANA, nDNA, ANCA) * Reduction of C3 levels. * eGFR\<90/ml/min/1,73 m2 valuated according to revised Bedside Schwartz Formula for patients between 2 and 17 years and with CKD-EPI Creatinine 2009 Equation for 18 years old patients. * Pregnancy * Neoplasm * Infections: previous or actual HBV (with HBeAb positivity) or HCV infection CD20 B lymphocytes count \<2,5% * Treatment with Rituximab in the last 6 months

What they're measuring

Comparison between RTX and MMF, considering remission intervals (in months) in the two cohorts

Timeframe: 12-24 months

Trial details

NCT IDNCT04585152

SponsorIstituto Giannina Gaslini

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-09-30

Contact for this trial

GianMarco Ghiggeri, MD

+39 010 56363523 gmarcoghiggeri@gaslini.org